Abstract：
Iris-fixated intraocular lens (IOL) is considered a safe and effective option for the correction of aphakia in patients with insufficient capsular support. This systematic review aims to summarize the existing evidence about the Artisan/Verisyse IOLs and to assess the influence of the IOL position on the postoperative outcomes. Three different databases were used for this systematic review and metaanalysis (PubMED, Scopus, and Embase). We searched for case series or clinical trials comparing the prepupillary versus retropupillary Artisan/Verisyse implantation. The statistical analysis was performed with the programming language R (version 3.6.1 2019-07-05). The number of articles included in the meta-analysis was six, with 506 eyes included in total. We found no significant differences in postoperative corrected distance visual acuity (CDVA) (0.309 [0.089-0.528] vs. 0.32 [0.2-0.44]), spherical equivalent (SE) (0.0153 D [-0.362 to 0.393] vs. -0.329 D [-0.62 to - 0.038]), and central corneal cell density (CECD) (1669.85 cells [1605.949-2150.937] vs. 1635.99 cells [1413.64-1858.363]) between the prepupillary and the retropupillary implantation, respectively. There were no significant differences in the rates of cystoid macular edema (CME; 7.70% vs. 9.8%), pupil deformation (4.5% vs. 5.4% retropupillary), or IOL luxation (2.3% and 2.2%). We found little influence of the IOL position in the postoperative analyzed outcomes. Thus, the implant position should be based on the surgeon\'s technical experience. Double-blind randomized prospective studies would improve the available evidence on the best implant position for the Artisan/Verisyse IOL.
摘要：
虹膜固定人工晶状体（IOL）被认为是一种安全有效的治疗无晶状体眼的方法。本系统综述旨在总结Artisan/Verisyse人工晶状体的现有证据，并评估人工晶状体位置对术后结局的影响。三个不同的数据库用于本系统综述和荟萃分析(PubMED，Scopus,和Embase）。我们搜索了病例系列或临床试验，比较了瞳孔前和瞳孔后Artisan/Verisyse植入。统计分析使用编程语言R(版本3.6.12019-07-05)进行。纳入荟萃分析的文章数量为六篇，共包括506只眼睛。我们发现术后矫正视力（CDVA）没有显着差异（0.309[0.089-0.528]vs.0.32[0.2-0.44])，球形当量（SE）（0.0153D[-0.362至0.393]vs.-0.329D[-0.62至-0.038])，和中央角膜细胞密度（CECD）（1669.85细胞[1605.949-2150.937]vs.1635.99细胞[1413.64-1858.363]）在瞳孔前和瞳孔后植入之间，分别。黄斑囊样水肿的发生率没有显着差异（CME;7.70％vs.9.8%），瞳孔变形(4.5%vs.5.4%后瞳孔)，或IOL脱位（2.3％和2.2％）。我们发现IOL位置对术后分析结果的影响很小。因此，植入位置应基于外科医生的技术经验。双盲随机前瞻性研究将改善Artisan/VerisyseIOL最佳植入位置的现有证据。
